Resistant Hypertension Optimal Treatment
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2000 participants.
Also called NCT01643434
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,000 participants
- Registry
-
NCT01643434
-
- Other papers using this trial's data
- Resistant hypertension optimal treatment trial: a randomized controlled trial
- Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment)
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Brazil
- Registry status
- Unknown status
Technical summary
Registry record NCT01643434. Randomized; no masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2013-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Resistant Hypertension Optimal Treatment
- Acronym
- ReHOT
- Condition
- Hypertension
- Intervention (Drug)
- Spironolactone
- Intervention (Drug)
- Clonidine
- Lead sponsor
- Instituto do Coracao
- Collaborator
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Record details
- Record id
cardio:ct-nct01643434- Content hash
3e1df73ae450bcc7645df6acf165c4aa621773cd25cf6d909ca897811b6b2eb0